All CHAMP Study Articles
-
772ClinicalPediatric Ophthalmologists Dive Deep on Low-Dose Atropine for Myopia Management
sponsored content August 15, 2023 By Kristen Dalli, Managing Editor, Review of Myopia Management ‘Pediatric ophthalmologists are the tip of the spear....
-
922Research ReviewCHAMP Study Three-Year Results
June 15, 2023 By Dwight Akerman, OD, MBA, FAAO, FBCLA, FIACLE In a new study recently published in JAMA Ophthalmology, a novel preservative-free...
-
542Latest Myopia NewsFDA Accepts Vyluma’s New Drug Application for NVK002 Atropine
June 6, 2023 BRIDGEWATER, N.J. — The U.S. Food and Drug Administration (FDA) has accepted Vyluma’s new drug application (NDA) for its...
-
1.5KClinicalThe Ins and Outs of Vyluma’s CHAMP Study
sponsored content June 1, 2023 By Kristen Dalli, Managing Editor, Review of Myopia Management At this year’s Global Specialty Lens Symposium, Mark...
-
831Latest Myopia NewsMyopia Research Highlights from the ARVO 2023 Meeting
May 3, 2023 By Dwight Akerman, OD, MBA, FAAO, FBCLA, FIACLE A gold mine for cutting-edge myopia research, the ARVO Meeting, held...
-
1.9KClinicalVyluma CHAMP Pivotal Phase 3 Clinical Trial Q&A
sponsored content October 27, 2022 Vyluma aims to preserve the vision of a global population by providing meaningful and effective pharmaceutical ophthalmic...
-
1.0KLatest Myopia NewsVyluma Checks Off Last Patient Visit for NVK002 Clinical Trial
September 1, 2022 BRIDGEWATER, N.J. — Vyluma has checked off an important step in its Phase III CHAMP (Childhood Atropine for Myopia...
-
2.9KClinicalVyluma: Leading with Innovation
sponsored content October 1, 2021 By Dwight Akerman, OD, MBA, FAAO, FBCLA Vyluma is dedicated to using its deep expertise to develop...
-
4.2KLatest Myopia NewsNevakar and Théa Enter Licensing Agreement for NVK-002 Atropine in Europe
February 1, 2021 BRIDGEWATER, N.J. and Clermont-Ferrand, France – Nevakar Inc. and Laboratoires Théa entered an exclusive licensing agreement for the commercialization...